BLASUBCUTANEOUSINJECTABLE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OMVOH (mirikizumab-mrkz) by Eli Lilly and Company is interleukin-23 antagonists [moa]. Approved for interleukin-23 antagonist [epc]. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMVOH (mirikizumab-mrkz) is a monoclonal antibody that antagonizes interleukin-23 (IL-23), a key cytokine driving inflammatory immune responses. It is administered subcutaneously for treatment of IL-23-driven inflammatory conditions. The drug was approved by the FDA on October 26, 2023, and represents Eli Lilly's entry into the competitive IL-23 antagonist space.
Growth
Early-stage growth product with moderate competitive pressure (30/100) and significant market share opportunity as a newer IL-23 antagonist from a major pharma sponsor.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OMVOH offers career opportunity at a critical growth inflection point for a newly approved biologic from Eli Lilly's immunology franchise. The moderate competitive pressure and early market penetration phase create demand for skilled commercial, medical, and reimbursement roles focused on market share defense and indication expansion.
Brand Manager
Worked on OMVOH at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.